接受治疗耐药抑郁症药物治疗的老年人认知变化:对OPTIMUM随机对照试验的二次分析
Hanadi A Oughli1, Nicholas J Ainsworth2, Meryl A Butters3
1Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.
The lancet. Healthy longevity
|November 14, 2025
概括
这项研究发现,使用各种药物治疗的治疗耐药抑郁症的老年人整体认知功能没有显著差异. 然而,阿里皮普拉增强剂和诺特林单疗法在抑制控制方面显示出适度的改善.
科学领域:
- 老年精神病学是一门精神病学专业.
- 神经科学是一个神经科学.
- 临床药理学 临床药理学
背景情况:
- 老年人治疗耐药性抑郁症 (TRD) 治疗的认知影响尚不清楚.
- 这项研究评估了TRD患者接受各种药物治疗策略的老年人急性认知变化.
研究的目的:
- 评估不同抗抑郁药物药物治疗策略对TRD老年人认知功能的影响.
- 为了比较与阿里皮普拉,布洛普里昂,和诺特林治疗相关的认知变化.
主要方法:
- 对OPTIMUM试验的二次分析,这是一项随机比较有效性试验,涉及60岁以上的TRD成年人.
- 参与者接受了抗抑郁药物增强剂 (阿里皮普拉,布洛,) 或在10周内转换为单一疗法 (布洛,北素).
- 认知功能主要使用NIH工具箱流体认知复合分数进行评估.
主要成果:
- 药物治疗组之间没有观察到整体流体认知综合评分的显著差异.
- 与第一步的布洛增强相比,阿里皮普拉的增强显示出抑制控制的适度增加.
- 与第二步的增强相比,诺特林单一治疗显示抑制控制的显著增加.
结论:
- 全球认知功能在老年人TRD评估的药物治疗策略中没有显著差异.
- 阿里皮普拉增强剂和诺特林单疗可能为这种人群的抑制控制提供特定的益处.
相关概念视频
Drug Dosing: Geriatric Patients
215
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
215
Pharmacodynamics in Geriatric Patients: Effects of Age
180
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
180
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
188
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
188
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
213
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
213
Antidepressant Drugs: MAOIs and Other Agents
784
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
784
Alzheimer's Disease: Treatment
782
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
782


